Evidence map›Paper›PMID 41399259›Full record

ArticleCell cycle (Georgetown, Tex.)2026

Targeting IMPDH to inhibit SAMHD1 in

Yolande Klootsema, Nikolaos Tsesmetzis, Sushma Sharma, Sophia Hofmann, Jonas Thier, Christopher Dirks, Femke M Hormann, Miriam Yagüe-Capilla, Anna Bohlin, Sofia Bengtzen and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yolande KlootsemaDivision of Paediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Nikolaos TsesmetzisDivision of Paediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Sushma SharmaDepartment of Medical Biochemistry and Biophysics, Umeå University, Umeå, Sweden.
Sophia HofmannCenter for Haematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Huddinge, Sweden.
Jonas ThierCenter for Haematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Huddinge, Sweden.
Christopher DirksScience for Life Laboratory (SciLifeLab), Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Femke M HormannScience for Life Laboratory (SciLifeLab), Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Miriam Yagüe-CapillaScience for Life Laboratory (SciLifeLab), Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Anna BohlinCenter for Haematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Huddinge, Sweden.
Sofia BengtzenCenter for Haematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Huddinge, Sweden.
Sören LehmannDepartment of Medicine, Division of Hematology, Karolinska University Hospital, Huddinge, Sweden.
Andrei ChabesDepartment of Medical Biochemistry and Biophysics, Umeå University, Umeå, Sweden.
Martin JäderstenCenter for Haematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Huddinge, Sweden.
Vanessa LundinCenter for Haematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Huddinge, Sweden.
Sean G RuddScience for Life Laboratory (SciLifeLab), Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Ingrid LilienthalDivision of Paediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Nikolas HeroldDivision of Paediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytarabine (ara-C) and fludarabine (F-ara-A) are key drugs in leukaemia treatment. SAMHD1 is known to confer resistance to ara-C and F-ara-A, and we previously identified ribonucleotide reductase inhibitors as indirect SAMHD1 inhibitors in a phenotypic screen. The inosine monophosphate dehydrogenase (IMPDH) inhibitor mycophenolic acid (MPA) was also a hit in this screen. IMPDH inhibitors (IMPDHi) have previously shown efficacy against

Indexed as

Enzyme InhibitorsGene RearrangementHistone-Lysine N-MethyltransferaseIMP DehydrogenaseLeukemia, Myeloid, AcuteMyeloid-Lymphoid Leukemia ProteinSAM Domain and HD Domain-Containing Protein 1Cell Line, TumorCytarabineDrug SynergismHumansVidarabineCytarabineEnzyme InhibitorsfludarabineHistone-Lysine N-MethyltransferaseIMP DehydrogenaseKMT2A protein, humanMyeloid-Lymphoid Leukemia ProteinSAM Domain and HD Domain-Containing Protein 1SAMHD1 protein, humanVidarabineIMPDHKMT2AleukemiaSAMHD1therapy resistance

Identifiers

PMID41399259
PMCPMC12915856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.